Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
186RNL for Leptomeningeal Metastases
NCT05034497Phase 1Completed
- Sponsor
- Cerenome
- Start
- Dec 2021
- Primary completion
- Oct 2026
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rhenium (186Re) obisbemeda in leptomeningeal metastasis (LM), sponsored by Cerenome. Primary endpoints: Adverse Events at 12 months and Dose-Limiting Toxicities at 12 months. Started Dec 2021; status: completed.
02
Drugs
rhenium (186Re) obisbemeda
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT05034497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034497.